Claims for Patent: 10,398,660
✉ Email this page to a colleague
Summary for Patent: 10,398,660
Title: | Imaging composition and uses thereof |
Abstract: | The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal center, particularly for the imaging of tumors. |
Inventor(s): | Donnelly; Paul Stephen (Brunswick East, AU), Rudd; Stacey Erin (Melbourne, AU), Williams; Spencer John (Coburg, AU) |
Assignee: | The University of Melbourne (Melbourne, AU) |
Application Number: | 15/963,599 |
Patent Claims: | 1. A conjugate of: a compound of formula (I): ##STR00011## or a pharmaceutically acceptable salt thereof, and an antibody, wherein L is a leaving group selected from
azide, halogen, cyanate and OR, wherein R is selected from C.sub.1 to C.sub.10 alkyl, C.sub.1 to C.sub.10 heteroalkyl, C.sub.2 to C.sub.10 alkene, C.sub.2 to C.sub.10 alkyne, and aryl, each of which is optionally substituted.
2. The conjugate of claim 1, wherein L is OR. 3. The conjugate of claim 2, wherein R is C.sub.1 to C.sub.6 alkyl. 4. The conjugate of claim 2, wherein OR is selected from O-p-toluenesulfonate, O-methanesulfonate, O-trifluoromethanesulfonate, O-benzenesulfonate, and O-m-nitrobenzenesulfonate. 5. The conjugate of claim 1, wherein the antibody is selected from trastuzumab, rituximab and cetuximab. 6. The conjugate of claim 1, wherein the antibody is selected from ranibizumab, bevacizumab, fresolimumab, panitumumab, pertuzumab, and ofatumumab. |
Details for Patent 10,398,660
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2034-10-16 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2034-10-16 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2034-10-16 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2034-10-16 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2034-10-16 |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2034-10-16 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.